Toubro, Søren

Meta-analysis of resting metabolic rate in formerly obese subjects

Astrup, A., Gøtzsche, P. C., van de Werken, K., Ranneries, C., Toubro, S., Raben, A., & Buemann, B. (1999) · The American Journal of Clinical Nutrition

Obesity, Physical Activity, DietRegulation of Appetite and Obesity

Cited by 296

Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein, vegetable protein, and carbohydrate

Mikkelsen, P. B., Toubro, S., & Astrup, A. (2000) · The American Journal of Clinical Nutrition

Regulation of Appetite and ObesityMuscle metabolism and nutrition

Cited by 293

Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men

Larsen, T. M., Toubro, S., van Baak, M. A., Gottesdiener, K. M., Larson, P., Saris, W. H., & Astrup, A. (2002) · The American Journal of Clinical Nutrition

Pharmacology and Obesity TreatmentAdipose Tissue and Metabolism

Cited by 179

Acute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men

van Baak, M. A., Hul, G. B. J., Toubro, S., Astrup, A., Gottesdiener, K. M., DeSmet, M., & Saris, W. H. M. (2002) · Clinical Pharmacology & Therapeutics

Adipose Tissue and MetabolismPharmacology and Obesity Treatment

Cited by 103

Fat Oxidation before and after a High Fat Load in the Obese Insulin-Resistant State

Blaak, E. E., Hul, G., Verdich, C., Stich, V., Martinez, A., Petersen, M., Feskens, E. F. M., Patel, K., Oppert, J. M., Barbe, P., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 97

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 80

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 46

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 46